$ALMS

Pangali Sanam sold $140K of ALMS

Pangali Sanam (Chief Legal Officer) sold 5,000 shares of ALUMIS INC. (ALMS) at $28.00 ($0.14M total) on 2026-07-06.

Original reporting
SEC EDGAR · Pangali Sanam
Published Jul 8, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity. It may influence short-term sentiment, but it does not provide new operational or financial information about ALMS.

02

Market read

Traders may monitor insider activity, but this specific sale is unlikely to change valuation without accompanying company fundamentals.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, liquidity needs, or whether other planned sales occurred.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-08 after-hours; reflects sale executed 2026-07-06.

Background

This is an SEC Form 4 insider transaction for ALUMIS INC. (ALMS) by its Chief Legal Officer.

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

SEC Form 4 shows ALMS Chief Legal Officer Pangali Sanam sold 5,000 shares at $28.00 on 2026-07-06 for $140,000.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, or corporate event. The disclosed sale size is modest and does not indicate a company-specific catalyst.

Market effects

No clear sector read-across from a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax or diversification-driven and may not reflect negative views, especially when holdings remain substantial.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Pangali Sanam

    Chief Legal Officer who sold 5,000 shares at $28.00.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor